SG Americas Securities
TVRD

SG Americas Securities’s Tvardi Therapeutics TVRD Stock Holding History

SG Americas Securities’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-444
Closed -$15K – 3392
2024
Q1 		$15K Sell
444
-1,559
-78% -$40.4K ﹤0.01% 2879
2023
Q4 		$54K Buy
2,003
+115
+6% +$4.76K ﹤0.01% 2905
2023
Q3 		$114K Buy
1,888
+501
+36% +$47K ﹤0.01% 2704
2023
Q2 		$141K Sell
1,387
-698
-33% -$96.2K ﹤0.01% 1943
2023
Q1 		$369K Buy
2,085
+750
+56% +$251K ﹤0.01% 1949
2022
Q4 		$516K Buy
1,335
+47
+4% +$17.9K 0.01% 1506
2022
Q3 		$434K Sell
1,288
-516
-29% -$187K 0.01% 1679
2022
Q2 		$593K Sell
1,804
-289
-14% -$101K 0.01% 1817
2022
Q1 		$915K Sell
2,093
-443
-17% -$182K 0.01% 1487
2021
Q4 		$1.11M Sell
2,536
-40
-2% -$20.1K 0.01% 1578
2021
Q3 		$1.43M Buy
2,576
+1,780
+224% +$893K 0.01% 1582
2021
Q2 		$409K Sell
796
-716
-47% -$454K ﹤0.01% 2033
2021
Q1 		$1.18M Sell
1,512
-2,680
-64% -$1.83M 0.01% 1412
2020
Q4 		$2.28M Buy
4,192
+495
+13% +$259K 0.01% 1010
2020
Q3 		$1.69M Buy
3,697
+463
+14% +$269K 0.01% 845
2020
Q2 		$1.99M Buy
3,234
+2,427
+301% +$1.34M 0.02% 839
2020
Q1 		$384K Buy
807
+296
+58% +$161K ﹤0.01% 2045
2019
Q4 		$297K Buy
511
+127
+33% +$89.1K ﹤0.01% 2201
2019
Q3 		$253K Sell
384
-415
-52% -$345K ﹤0.01% 2244
2019
Q2 		$618K Buy
799
+255
+47% +$179K ﹤0.01% 1756
2019
Q1 		$385K Sell
544
-2,421
-82% -$1.45M ﹤0.01% 2066
2018
Q4 		$1.39M Buy
+2,965
New +$1.91M 0.01% 1112
2017
Q4 		– Sell
-704
Closed -$347K – 3704
2017
Q3 		$347K Buy
+704
New +$353K ﹤0.01% 2118

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SG Americas Securities's TVRD Position: Q2 2024 in Review

SG Americas Securities sold out of Tvardi Therapeutics (TVRD) in Q2 2024, closing a stake of 444 shares — an estimated $15K sold.

SG Americas Securities first reported a position in TVRD in Q3 2017 and held it in 23 quarters. The position peaked at $2.28M in Q4 2020. 79 funds tracked by Wall St. Rank hold TVRD as of Q2 2024.

  • SG Americas Securities reported no remaining Tvardi Therapeutics position as of Q2 2024 after selling out during the quarter.
  • SG Americas Securities sold 444 Tvardi Therapeutics shares in Q2 2024, an estimated $15K.
  • SG Americas Securities first reported a position in Tvardi Therapeutics in Q3 2017 and held it in 23 quarters.
  • SG Americas Securities's Tvardi Therapeutics position peaked at $2.28M in Q4 2020.
  • 79 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2024.

Based on SG Americas Securities's 13F filing for Q2 2024, filed 12 Jul 2024.